← Back to Search

Registry for Vascular Anomalies Associated With Coagulopathy (VAC Trial)

N/A
Waitlist Available
Led By Beth Drolet, MD
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Subjects with a vascular anomaly with coagulopathy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after dna collected and batches are sent for analysis
Awards & highlights
No Placebo-Only Group

Summary

PURPOSE The purpose of this study is to learn more about multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT). MLT is a rare vascular disorder characterized by multiple congenital skin and visceral lesions, profound thrombocytopenia, and gastrointestinal bleeding. The skin lesions may appear red, brown or blue, often misdiagnosed as hemangiomas. The gastrointestinal tract, liver, and lungs are the most common internal organs involved. The severe thrombocytopenia (low platelets) is believed to be the result of platelet trapping within the skin and visceral vascular lesions. Severe and chronic gastrointestinal bleeding is common during infancy and early childhood. Although a relatively newly described entity, MLT was likely previously reported as hemangiomas, blue rubber bleb nevus syndrome, diffuse hemangiomatosis, Kasabach-Merritt phenomenon, and hereditary hemorrhagic telangiectasia. The term cutaneovisceral angiomatosis with thrombocytopenia is also a term used for this same disease. This study is a longitudinal cohort study of MLT to collect detailed clinical data on the distribution of disease, disease severity, and complications. This data will be used to create diagnostic criteria and an evaluation protocol for infants with this disease

Eligible Conditions
  • Kaposi sarcoma
  • Thrombocytopenic Purpura
  • Birthmark
  • Cutaneovisceral Angiomatosis Syndrome

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after dna collected and batches are sent for analysis
This trial's timeline: 3 weeks for screening, Varies for treatment, and after dna collected and batches are sent for analysis for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of patients with genetic mutations, copy number variations and/or expression analysis

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Vascular Anomaly with CoagulopathyExperimental Treatment1 Intervention
All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) or with a vascular anomaly with coagulopathy

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
635 Previous Clinical Trials
1,181,672 Total Patients Enrolled
Beth Drolet, MDPrincipal InvestigatorMedical College of Wisconsin
4 Previous Clinical Trials
771 Total Patients Enrolled
Ulrich Broeckel, MDPrincipal InvestigatorMedical College of Wisconsin
Howard Jacob, PhDPrincipal InvestigatorMedical College of Wisconsin
Michael Kelly, MD, PhDPrincipal InvestigatorMedical College of Wisconsin
2 Previous Clinical Trials
42 Total Patients Enrolled
Richard Noel, MD, PhDPrincipal InvestigatorMedical College of Wisconsin
Paula North, MD, PhDPrincipal InvestigatorMedical College of Wisconsin
~2 spots leftby Dec 2025